Close

Press Releases

AstraZeneca plans to invest $50 billion in America for...

AstraZeneca announces $50 billion of investment in the United States by 2030, building on America’s global leadership in medicines manufacturing and R&D. This investment is...

Merck to Initiate Phase 3 Trials for Investigational Once-Monthly...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the EXPrESSIVE Phase 3 clinical trials, evaluating...

GREENFIELD GLOBAL TAPS INDUSTRY VETERAN VEY GAROFALO TO DRIVE...

Accomplished industry leader to continue driving growth and product expansion across life sciences, flavors, fragrances, and specialty segments Greenfield Global Inc., a leading global producer, manufacturer,...

Optibrium secures multi-million-pound financing package from Shawbrook to accelerate...

Proceeds will accelerate Optibrium’s product development and expand the global reach of its computational chemistry and AI-driven discovery technology.  CAMBRIDGE, UK, 08 July 2025 – Optibrium, a...

Aptar CSP Technologies’ Dual-Active Material Science Technology Simultaneously Controls...

Dual-active material science solution is ideal for sensitive formulations Auburn, AL, July 8, 2025 – Aptar CSP Technologies, part of AptarGroup, Inc. and a leader in...

datma Launches Federated Biomarker Explorer with Free Access to...

Pharma teams can now assess biomarker coverage across datma's federated network with no cost, contracts, or IT support required. datma, a leader in federated real-world data...

Infudopa SubC Parkinsons Therapy: Neuraxpharm-Dizlin Deal

Neuraxpharm Group (“Neuraxpharm”), a leading European specialty pharmaceutical company dedicated to central nervous system (CNS) disorders, and Dizlin Pharmaceuticals AB (“Dizlin”), a Swedish R&D company...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read